Captor Therapeutics Spolka Akcyjna (CTX.WA)
PLN 35.4
(5.36%)
PLN 35.4
(5.36%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 3.77 Million PLN | -45.66% |
| 2022 | 6.95 Million PLN | -15.02% |
| 2021 | 8.18 Million PLN | -34.27% |
| 2020 | 12.44 Million PLN | 21.02% |
| 2019 | 10.28 Million PLN | -5.28% |
| 2018 | 10.85 Million PLN | 283.1% |
| 2017 | 2.83 Million PLN | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 6.35 Million PLN | 121.37% |
| 2024 Q1 | 2.86 Million PLN | -24.06% |
| 2023 Q3 | 4.52 Million PLN | -12.67% |
| 2023 Q2 | 5.17 Million PLN | -13.42% |
| 2023 FY | 3.77 Million PLN | -45.66% |
| 2023 Q4 | 3.77 Million PLN | -16.47% |
| 2023 Q1 | 5.98 Million PLN | -13.95% |
| 2022 Q1 | 7.03 Million PLN | -13.97% |
| 2022 Q4 | 6.95 Million PLN | -16.29% |
| 2022 FY | 6.95 Million PLN | -15.02% |
| 2022 Q3 | 8.3 Million PLN | 56.58% |
| 2022 Q2 | 5.3 Million PLN | -24.64% |
| 2021 Q2 | 11.58 Million PLN | -10.94% |
| 2021 FY | 8.18 Million PLN | -34.27% |
| 2021 Q1 | 13 Million PLN | 4.49% |
| 2021 Q4 | 8.18 Million PLN | -16.97% |
| 2021 Q3 | 9.85 Million PLN | -14.93% |
| 2020 FY | 12.44 Million PLN | 21.02% |
| 2020 Q2 | 10.34 Million PLN | 0.0% |
| 2020 Q4 | 12.44 Million PLN | 0.0% |
| 2019 FY | 10.28 Million PLN | -5.28% |
| 2019 Q4 | 10.28 Million PLN | 0.0% |
| 2018 FY | 10.85 Million PLN | 283.1% |
| 2017 FY | 2.83 Million PLN | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Bioceltix S.A. | 175.05 Thousand PLN | -2058.154% |
| BIOTON S.A. | 68.69 Million PLN | 94.5% |
| Mabion S.A. | 35.82 Million PLN | 89.455% |
| Molecure S.A. | 7.13 Million PLN | 47.082% |
| NanoGroup S.A. | - PLN | -Infinity% |
| Pharmena S.A. | 181 Thousand PLN | -1987.293% |
| Poltreg S.A. | 8.19 Million PLN | 53.893% |
| Pure Biologics Spólka Akcyjna | 12.93 Million PLN | 70.799% |
| Ryvu Therapeutics S.A. | 906 Thousand PLN | -316.998% |
| Synthaverse S.A. | 70.04 Million PLN | 94.606% |
| Urteste S.A. | 627 Thousand PLN | -502.552% |